- November 17, 2009
- Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors.
- >> more
- November 12, 2009
- Mersana Therapeutics Publishes Review Article Detailing Advantages of its Lead Cancer Compound in Journal of Advanced Drug Delivery Reviews.
- >> more
|
|
Mersana Therapeutics employs its biodegradable polymer platform (Fleximer®) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.
|